ARALEN
LOE ApproachingNDAORALTABLET
Approved
Oct 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARALEN is an oral tablet approved in 1949 by Sanofi with unknown mechanism of action and indication profile. Specific therapeutic uses and pharmacologic class are not specified in available data. Patient population cannot be determined from provided information.
LOE Approaching
Product is approaching loss of exclusivity with low competitive pressure (30%), signaling potential team restructuring and shift toward lifecycle management strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate minimal active recruitment for ARALEN roles, reflecting LOE-approaching lifecycle stage. Career opportunities on this product are declining and focused on managed transition and market access optimization rather than growth initiatives.
Brand ManagerProduct Manager
Worked on ARALEN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.